A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7H3 Expressing Cancers

Trial Profile

A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7H3 Expressing Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Enoblituzumab (Primary) ; Pembrolizumab
  • Indications Cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors MacroGenics
  • Most Recent Events

    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 26 Aug 2015 Planned End Date changed from 1 Jun 2020 to 1 Aug 2020 as reported by ClinicalTrials.gov.
    • 26 Aug 2015 Planned primary completion date changed from 1 Jun 2018 to 1 Aug 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top